Skip to main content
SMFM 2026 Pregnancy Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared outside of the session
Faculty have requested this content not be shared outside of the session
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Recording available 2/16-5/2
Recording available 2/16-5/2
AIUM Credit
AIUM Credit
Foundation Awardee
Foundation Awardee
Poster Icons
Abstract Award
Abstract Award
Foundation Awardee
Foundation Awardee

Industry-Supported Learning

Advancing Preeclampsia Risk Assessment: Integrating the sFlt-1/PlGF Ratio into Clinical Practice

Sunday, February 8, 2026
12:00 PM - 1:00 PM  
Location: Academy 412- 414

Sponsored By 

    Industry Session Presenter(s)

  • Sarosh Rana, MD, MPH (she/her/hers)

    Professor of Obstetrics and Gynecology, Endowed Chris J. and Marie A. Olson Chair of Obstetrics and Gynecology, President of the Leland J. and Dorothy H. Olson Center for Women’s Health Advisory Committee
    The University of Nebraska Medical Center / Nebraska Medicine, Nebraska, United States

  • S Ananth Karumanchi, MD

    Professor of Medicine; Medallion Chair, Vascular Biology
    Cedars-Sinai Medical Center
    eCedars-Sinai Medical Center,, California, United States

  • Allyson Kozak, PhD, MBA, NRCC

    Sr. Scientific Manager, Mass Spec and Women’s Health
    Roche Diagnostics

This independent presentation is not part of the official program as planned by the SMFM Pregnancy Meeting™ Program Committee. The content of this session is not endorsed by or recommended by SMFM.

Learning Objectives:

  • Examine the evidence supporting the sFlt-1/PlGF ratio as a tool for assessing short-term preeclampsia risk and its role in clinical practice.
  • Understand the interpretation of the Elecsys sFlt-1/PlGF ratio to aid in identifying severe preeclampsia and adverse maternal-fetal outcomes.
  • Explore how integrating angiogenic biomarkers with standard assessments can enhance the monitoring and management of hypertensive disorders in pregnancy.
  • Discuss the potential of biomarker-based approaches to optimize healthcare resources and improve patient reassurance for low-risk cases.